C20 Sphingomyelin (d18:1/20:0) is associated with insulin resistance in obese humans and is upregulated in the hippocampus of streptozotocin-induced diabetic rats and in human plasma; it is also upregulated in the liver of mouse models of Niemann-Pick disease type C1, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder; plasma levels of C20 Sphingomyelin (d18:1/20:0) are decreased in patients with prostate cancer.